Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Color Additive Risk Evaluation Tool Qualified As New Medical Device Development Tool

Executive Summary

A color additive evaluation tool for polymeric medical devices was approved as an MDDT under the FDA’s voluntary program.

You may also be interested in...



Teamwork: FDA And NIH Join Forces To Fund Neurodegenerative Disease Research, Medical Device Development Tools

The two federal agencies are working together to research rare conditions and fund grants for small businesses creating medical device development tools.

Leveraging mHealth Data For Product Development: FDA-Supported Action Plan Released

Mobile health devices including wearable consumer products have the potential to collect a lot of medical information that can be useful for product development and tracking. A new action plan from US FDA, industry and other key players outlines ways to harness and use that data to bring better products to market more quickly.

Expanding The Medtech Toolbox: US FDA's 'Medical Device Development Tools' Program Rolls Out

Three years in the making, FDA has released a final guidance for medical device development tools that would allow developers to qualify their MDDTs and give medical device manufactures access to new tools that could help them prove safety and effectiveness of their products sooner.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel